172 related articles for article (PubMed ID: 21193417)
1. White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.
Del Giudice I; Mauro FR; De Propris MS; Santangelo S; Marinelli M; Peragine N; Di Maio V; Nanni M; Barzotti R; Mancini F; Armiento D; Paoloni F; Guarini A; Foà R
Haematologica; 2011 Apr; 96(4):626-30. PubMed ID: 21193417
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.
Weinberg JB; Volkheimer AD; Chen Y; Beasley BE; Jiang N; Lanasa MC; Friedman D; Vaccaro G; Rehder CW; Decastro CM; Rizzieri DA; Diehl LF; Gockerman JP; Moore JO; Goodman BK; Levesque MC
Am J Hematol; 2007 Dec; 82(12):1063-70. PubMed ID: 17654680
[TBL] [Abstract][Full Text] [Related]
3. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
4. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.
Bulian P; Rossi D; Forconi F; Del Poeta G; Bertoni F; Zucca E; Montillo M; Pozzato G; D'Arena G; Efremov DG; Marasca R; Lauria F; Gaidano G; Gattei V; Laurenti L
J Transl Med; 2012 Jan; 10():18. PubMed ID: 22289136
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
Xu M; Fan L; Miao KR; Liu P; Xu W; Li JY
Med Oncol; 2012 Sep; 29(3):2102-10. PubMed ID: 21881978
[TBL] [Abstract][Full Text] [Related]
6. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
[TBL] [Abstract][Full Text] [Related]
7. Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome.
Tobin G; Thunberg U; Laurell A; Karlsson K; Aleskog A; Willander K; Söderberg O; Merup M; Vilpo J; Hultdin M; Sundström C; Roos G; Rosenquist R
Haematologica; 2005 Apr; 90(4):465-9. PubMed ID: 15820941
[TBL] [Abstract][Full Text] [Related]
8. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.
Kröber A; Seiler T; Benner A; Bullinger L; Brückle E; Lichter P; Döhner H; Stilgenbauer S
Blood; 2002 Aug; 100(4):1410-6. PubMed ID: 12149225
[TBL] [Abstract][Full Text] [Related]
9. Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells.
Yin CC; Tang G; Lu G; Feng X; Keating MJ; Medeiros LJ; Abruzzo LV
Mod Pathol; 2015 Aug; 28(8):1130-7. PubMed ID: 25953391
[TBL] [Abstract][Full Text] [Related]
10. Defining the prognosis of early stage chronic lymphocytic leukaemia patients.
Pepper C; Majid A; Lin TT; Hewamana S; Pratt G; Walewska R; Gesk S; Siebert R; Wagner S; Kennedy B; Miall F; Davis ZA; Tracy I; Gardiner AC; Brennan P; Hills RK; Dyer MJ; Oscier D; Fegan C
Br J Haematol; 2012 Feb; 156(4):499-507. PubMed ID: 22171799
[TBL] [Abstract][Full Text] [Related]
11. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
[TBL] [Abstract][Full Text] [Related]
12. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia.
Molica S; Vitelli G; Cutrona G; Todoerti K; Mirabelli R; Digiesi G; Giannarelli D; Sperduti I; Molica M; Gentile M; Morabito F; Neri A; Ferrarini M
Int J Hematol; 2008 Nov; 88(4):374-380. PubMed ID: 18818986
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
[TBL] [Abstract][Full Text] [Related]
15. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.
Austen B; Powell JE; Alvi A; Edwards I; Hooper L; Starczynski J; Taylor AM; Fegan C; Moss P; Stankovic T
Blood; 2005 Nov; 106(9):3175-82. PubMed ID: 16014569
[TBL] [Abstract][Full Text] [Related]
17. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
Mato A; Nabhan C; Kay NE; Lamanna N; Kipps TJ; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Kiselev P; Swern AS; Bhushan S; Sullivan K; Flick ED; Sharman JP
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):114-124.e2. PubMed ID: 29352719
[TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status.
Dreger P; Stilgenbauer S; Benner A; Ritgen M; Kröber A; Kneba M; Schmitz N; Döhner H
Blood; 2004 Apr; 103(7):2850-8. PubMed ID: 14670929
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of immunoglobulin variable heavy chain gene mutation status: long term follow-up in a series of chronic lymphocytic leukemia patients.
Panovska-Stavridis I; Cevreska L; Stojanovic A; Efremov D
Prilozi; 2006 Dec; 27(2):127-37. PubMed ID: 17211297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
